Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK

International Journal of Oncology

Volumn 38, Issue 3, 2011, Pages 879-885

  Relja, Borna ^a   Meder, Frank ^a   Wang, Minhong ^a   Blaheta, Roman ^a   Henrich, Dirk ^a   Marzi, Ingo ^a   Lehnert, Mark ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Adhesion; Cancer; Integrins; Liver; ROCK; Simvastatin

Indexed keywords

ALPHA2 INTEGRIN; BETA1 INTEGRIN; BETA3 INTEGRIN; INTEGRIN; INTEGRIN RECEPTOR; RHO FACTOR; SIMVASTATIN;

ARTICLE; CANCER GROWTH; CANCER INVASION; CARCINOMA CELL; CELL ADHESION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL COMMUNICATION; CELL PROLIFERATION; CELLS, CULTURED; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL CELLS; HEP G2 CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTEGRINS; LIVER NEOPLASMS; MEVALONIC ACID; RHO-ASSOCIATED KINASES; SIMVASTATIN;

EID: 79952010116     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2010.892     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin 59: 225-249, 2009.
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M and Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592, 2007.
3. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006. (Pubitemid 46655601)
4. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, Krieger NR and Schwartz ME: Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 10: 534-540, 2004. (Pubitemid 38443593)
5. Morris-Stiff G, Gomez D, de Liguori CN and Prasad KR: Surgical management of hepatocellular carcinoma: is the jury still out? Surg Oncol 18: 298-321, 2009.
6. Goldstein JL and Brown MS: Regulation of the mevalonate pathway. Nature 343: 425-430, 1990.
7. Fromigue O, Hay E, Modrowski D, Bouvet S, Jacquel A, Auberger P and Marie PJ: RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ 13: 1845-1856, 2006.
8. Riganti C, Doublier S, Costamagna C, Aldieri E, Pescarmona G, Ghigo D and Bosia A: Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol 74: 476-484, 2008.
9. Charni F, Friand V, Haddad O, Hlawaty H, Martin L, Vassy R, Oudar O, Gattegno L, Charnaux N and Sutton A: Syndecan-1 and syndecan-4 are involved in RANTES/CCL5-induced migration and invasion of human hepatoma cells. Biochim Biophys Acta 1790: 1314-1326, 2009.
10. Wong CC, Wong CM, Tung EK, Man K and Ng IO: Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. Hepatology 49: 1583-1594, 2009.
11. Ghosh-Choudhury N, Mandal CC, Ghosh-Choudhury N and Ghosh-Choudhury G: Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. Cell Signal 22: 749-758, 2010.
12. Cho SJ, Kim JS, Kim JM, Lee JY, Jung HC and Song IS: Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer 123: 951-957, 2008.
13. Sekine Y, Furuya Y, Nishii M, Koike H, Matsui H and Suzuki K: Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor. Biochem Biophys Res Commun 372: 356-361, 2008.
14. Hynes RO: Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69: 11-25, 1992.
15. Yam JW, Tse EY and Ng IO: Role and significance of focal adhesion proteins in hepatocellular carcinoma. J Gastroenterol Hepatol 24: 520-530, 2009.
16. Hindler K, Cleeland CS, Rivera E and Collard CD: The role of statins in cancer therapy. Oncologist 11: 306-315, 2006.
17. Newman A, Clutterbuck RD, Powles RL and Millar JL: Selective inhibition of primary acute myeloid leukaemia cell growth by simvastatin. Leukemia 8: 2023-2029, 1994. (Pubitemid 24985714)
18. Yang YC, Huang WF, Chuan LM, Xiao DW, Zeng YL, Zhou DA, Xu GQ, Liu W, Huang B and Hu Q: In vitro and in vivo study of cell growth inhibition of simvastatin on chronic myelogenous leukemia cells. Chemotherapy 54: 438-446, 2008.
19. Sutter AP, Maaser K, Hopfner M, Huether A, Schuppan D and Scherubl H: Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. J Hepatol 43: 808-816, 2005. (Pubitemid 41414506)
20. Paragh G, Kertai P, Kovacs P, Paragh G Jr, Fulop P and Foris G: HMG CoA reductase inhibitor fluvastatin arrests the development of implanted hepatocarcinoma in rats. Anticancer Res 23: 3949-3954, 2003. (Pubitemid 37474348)
21. Taras D, Blanc JF, Rullier A, Dugot-Senant N, Laurendeau I, Vidaud M and Rosenbaum J: Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity. J Hepatol 46: 69-76, 2007. (Pubitemid 44834427)
22. Kawata S, Kakimoto H, Ishiguro H, Yamasaki E, Inui Y and Matsuzawa Y: Effect of pravastatin, a potent 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on survival of AH130 hepatoma-bearing rats. Jpn J Cancer Res 83: 1120-1123, 1992. (Pubitemid 23009029)
23. Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y and Matsuzawa Y: Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 84: 886-891, 2001. (Pubitemid 32385829)
24. Graf H, Jungst C, Straub G, Dogan S, Hoffmann RT, Jakobs T, Reiser M, Waggershauser T, Helmberger T, Walter A, Walli A, Seidel D, Goke B and Jungst D: Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion 78: 34-38, 2008.
25. Lee J, Jung KH, Park YS, Ahn JB, Shin SJ, Im SA, Oh DY, Shin DB, Kim TW, Lee N, Byun JH, Hong YS, Park JO, Park SH, Lim HY and Kang WK: Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. Cancer Chemother Pharmacol 64: 657-663, 2009.
26. Desgrosellier JS and Cheresh DA: Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10: 9-22, 2010.
27. Fu BH, Wu ZZ and Qin J: Effects of integrins on laminin chemotaxis by hepatocellular carcinoma cells. Mol Biol Rep 37: 1665-1670, 2009.
28. Song G, Luo Q, Qin J, Wang B and Cai S: Expression of integrin beta1 and its roles on adhesion between different cell cycle hepatocellular carcinoma cells (SMMC-7721) and human umbilical vein endothelial cells. Colloids Surf B Biointerfaces 34: 247-252, 2004. (Pubitemid 38447016)
29. Zhang H, Ozaki I, Mizuta T, Matsuhashi S, Yoshimura T, Hisatomi A, Tadano J, Sakai T and Yamamoto K: Beta 1-integrin protects hepatoma cells from chemotherapy induced apoptosis via a mitogen-activated protein kinase dependent pathway. Cancer 95: 896-906, 2002. (Pubitemid 34839683)
30. Zhao J, Dong L, Lu B, Wu G, Xu D, Chen J, Li K, Tong X, Dai J, Yao S, Wu M and Guo Y: Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology 135: 956-968, 2008.
31. Yang C, Zeisberg M, Lively JC, Nyberg P, Afdhal N and Kalluri R: Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res 63: 8312-8317, 2003. (Pubitemid 37549483)
32. Kawakami-Kimura N, Narita T, Ohmori K, Yoneda T, Matsumoto K, Nakamura T and Kannagi R: Involvement of hepatocyte growth factor in increased integrin expression on HepG2 cells triggered by adhesion to endothelial cells. Br J Cancer 75: 47-53, 1997. (Pubitemid 27007272)
33. Riento K and Ridley AJ: Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 4: 446-456, 2003. (Pubitemid 36648590)
34. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T and Narumiya S: An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 5: 221-225, 1999. (Pubitemid 29068531)
35. Takamura M, Sakamoto M, Genda T, Ichida T, Asakura H and Hirohashi S: Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632. Hepatology 33: 577-581, 2001. (Pubitemid 32185219)
36. Wang DS, Dou KF, Li KZ and Song ZS: Enhancement of migration and invasion of hepatoma cells via a Rho GTPase signaling pathway. World J Gastroenterol 10: 299-302, 2004.
37. Ma T, Zhao Y, Kwak YD, Yang Z, Thompson R, Luo Z, Xu H and Liao FF: Statin's excitoprotection is mediated by sAPP and the subsequent attenuation of calpain-induced truncation events, likely via rho-ROCK signaling. J Neurosci 29: 11226-11236, 2009.
38. Relja B, Lehnert M, Seyboth K, Bormann F, Hohn C, Czerny C, Henrich D and Marzi I: Simvastatin reduces mortality and hepatic injury after hemorrhage/resuscitation in rats. Shock 34: 46-54, 2010.